Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
2021 Year in Review - Multiple Myeloma
2021 Year in Review: Advances in Dual IO Cancer Treatments
2021 Year in Review - Breast Cancer
2021 Oncology Drug Coding and Updates
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer
2021 Year in Review - Biosimilars
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2021 Novel Oncology Drug Approvals
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
ASH 2021 - AML
ASH 2021 - Myelofibrosis
2021 Myelofibrosis Wrap-Up
AACR & ASCO 2021 - Midyear Review
ASCO 2021 - Lung Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Breast Cancer Monthly Minutes
Breast Cancer
Elacestrant May Improve Outcomes for Patients with Metastatic Breast Cancer Who Have Progressed on Previous Endocrine Therapy
By
Patricia Stewart
Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) elacestrant (RAD1901) significantly reduced the risk for death or disease progression and improved progression-free survival (PFS) compared with standard of care (SOC) endocrine therapy in patients with estrogen receptor (ER)-positive,
HER2
-negative metastatic breast cancer who had progressed on previous endocrine and targeted therapies, according to results of the phase 3 EMERALD clinical trial.
Read More ›
2021 Breast Cancer Year in Review Introduction
Breast Cancer
The COVID-19 pandemic continues to impact healthcare across the globe.
Read More ›
Highlights in Breast Cancer from ASCO 2021: An Interview with Virginia Kaklamani, MD
Breast Cancer
The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage,
HER2
-negative breast cancer and
BRCA1/2
mutations. This highlights the need to test for
BRCA1/2
mutations to determine if patients qualify for olaparib.
Read More ›
Polyunsaturated Fatty Acids, Exercise, and Fatigue in Breast Cancer
Breast Cancer
A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations.
Read More ›
A Web-Based Survey on Suggested Modifications in the Management of Patients with Breast Cancer During the COVID-19 Pandemic
Breast Cancer
Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available.
Read More ›
Real-World Patient-Reported Outcomes, Clinical Profile, and Treatment Patterns in a Subset of Patients with HR-Positive, HER2-Negative, Advanced Breast Cancer with Poor Prognostic Factors
Breast Cancer
In a real-world study, more than 60% of the HR-positive,
HER2
-negative advanced breast cancer samples had ≥1 disease-related poor prognostic factors. The need for more effective CDK4/6 inhibitor medication in these individuals is highlighted by their increased pain and impaired performance status.
Read More ›
Overall Survival in Patients with HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer Treated with a CDK4/6 Inhibitor plus Fulvestrant: An FDA Pooled Analysis
Breast Cancer
Adding CDK4/6 inhibitors to fulvestrant resulted in an improvement in overall survival. These findings back up the current standard of care of CDK4/6 inhibitors plus fulvestrant for patients with HR-positive,
HER2
-negative, advanced breast cancer.
Read More ›
A Summary of PARP Inhibitors for the Treatment of Breast Cancer
Breast Cancer
PARP inhibitors offer the possibility of biomarker-targeted treatment for breast cancer. Therefore, it is necessary to quickly identify which patients may benefit from treatment and to guarantee that genetic testing is available.
Read More ›
CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status: A Real-World Evidence Study
Breast Cancer
A real-world investigation has found that CDK4/6 inhibitor treatment outcomes are worse in patients with germline
BRCA
mutation–positive metastatic breast cancer than in patients with germline
BRCA
wild-type disease and unclear germline
BRCA
status, implying possible changes in tumor biology.
Read More ›
Olaparib Monotherapy in Germline BRCA Mutation–Positive, HER2-Negative Metastatic Breast Cancer in the Real-World Setting
Breast Cancer
Clinical studies have demonstrated that olaparib is clinically efficacious in patients with germline
BRCA
mutation–positive,
HER2
-negative metastatic breast cancer in a setting closely resembling the real world.
Read More ›
Page 1 of 15
1
2
3
4
5
6
7
8
9
10
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
2021 Year in Review - Multiple Myeloma
2021 Year in Review: Advances in Dual IO Cancer Treatments
2021 Year in Review - Breast Cancer
2021 Oncology Drug Coding and Updates
2021 Year in Review - Renal-Cell Carcinoma
2021 Year in Review - Ovarian Cancer
2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer
2021 Year in Review - Biosimilars
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2021 Novel Oncology Drug Approvals
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
ASH 2021 - AML
ASH 2021 - Myelofibrosis
2021 Myelofibrosis Wrap-Up
AACR & ASCO 2021 - Midyear Review
ASCO 2021 - Lung Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
OPM
Print Edition
OPM
Weekly e‑Newsletter
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
OPM
's
Privacy Policy
, and
OPM
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION